NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

CMMB

CMMB US Stock
$19.98
Open: $22.4 High: $22.79 Low: $19.19 Close: $19.85
Range: 2021-05-06 - 2021-05-07
Volume: 288,109
Market: Closed
Powered by Finage Stock APIDelayed data
CMMB
  • CEO:
  • Employees:
  • Sector:
  • Industry:
CMMB News
Latest news about the CMMB
  • Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

    Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibrosis.

    View More →
  • Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing

    Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the appointment of Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen to Chemomab's Board of Directors. Dr. Stephen Squinto will remain Chairman of Chemomab's Board. Dr. Adi Mor and Dr. Nissim Darvish will also continue in their prior role as Directors, where Dr. Darvish will serve as Chair of the Compensation Committee.

    View More →
  • Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months

    The Genesis Prize Foundation today announced that its co-founder Stan Polovets has stepped down as chairman of the board of Anchiano Therapeutics (NASDAQ ANCN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.

    View More →